Literature DB >> 15902860

Outcome of acetabular revision using an uncemented hydroxyapatite-coated component: two- to five-year results and review.

Armugam Dorairajan1, Ram Mohan Reddy, Stephen Krikler.   

Abstract

This is a retrospective review of 50 uncemented acetabular revisions with porous, hydroxyapatite-coated cups. The acetabulum alone was revised in 22 hips and both components were revised in 28 hips. The majority of hips (26) had type 2A (Paprosky) acetabular bone loss. All the revisions were carried out through a posterior approach. The mean duration of follow-up was 32 months (range, 24-52 months). Clinically, there was significant improvement in pain and moderate improvement in movement and mobility, and there is no radiological sign of failure of any cup so far. Re-revision was performed in 3 hips (6%) for recurrent dislocation. Our early results favor the use of this type of cup in acetabular revisions with moderate bone loss, but longer-term follow-up will be required. Key words: acetabulum, hydroxyapatite, revision, bone deficiency, complications.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15902860     DOI: 10.1016/j.arth.2004.09.049

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  3 in total

1.  Do tantalum and titanium cups show similar results in revision hip arthroplasty?

Authors:  S Mehdi Jafari; Benjamin Bender; Catelyn Coyle; Javad Parvizi; Peter F Sharkey; William J Hozack
Journal:  Clin Orthop Relat Res       Date:  2010-02       Impact factor: 4.176

2.  Effects of hydroxyapatite coating of cups used in hip revision arthroplasty.

Authors:  Stergios Lazarinis; Johan Kärrholm; Nils P Hailer
Journal:  Acta Orthop       Date:  2012-09-03       Impact factor: 3.717

3.  The effect of adhesive strength of hydroxyapatite coating on the stability of hydroxyapatite-coated prostheses in vivo at the early stage of implantation.

Authors:  Yonghong Duan; Shu Zhu; Fei Guo; Jinyu Zhu; Mao Li; Jie Ma; Qingsheng Zhu
Journal:  Arch Med Sci       Date:  2012-05-09       Impact factor: 3.318

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.